We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





AI Takes Guesswork Out Of Lateral Flow Testing

By LabMedica International staff writers
Posted on 19 Oct 2022

An artificial intelligence (AI) app to read COVID-19 lateral flow tests helped to reduce false results in a new trial. More...

A team of researchers from the University of Birmingham (Birmingham, UK), Durham University (Durham, UK) and Oxford University (Oxford, UK) tested whether a machine learning algorithm could improve the accuracy of results from antigen lateral flow devices for COVID-19. The LFD AI Consortium team worked at UK Health Security Agency assisted test centres and with health care workers conducting self-testing to trial the AI app. More than 100,000 images were submitted as part of the study, and the team found that the algorithm was able to increase the sensitivity of results, determining between a true positive and false negative, from 92% to 97.6% accuracy.

“The widespread use of antigen lateral flow devices was a significant moment not just during the pandemic, but has also introduced diagnostic testing to many more people in society. One of the drawbacks with LFD testing for COVID, pregnancy and any other future use is the ‘faint line’ question – where we can’t quite tell if it’s a positive or not,” said Professor Andrew Beggs, Professor of Cancer Genetics & Surgery at the University of Birmingham and lead author of the study. “The study looked at the feasibility of using machine learning to take the guesswork out of the faint line tests, and we’re pleased to see that the app saw an increase in sensitivity of the tests, reducing the numbers of false negatives. The promise of this type of technology could be used in lots of applications, both to reduce uncertainty about test results and provide a crucial support for visually impaired people.”

“The increase in sensitivity and overall accuracy is significant and it shows the potential of this app by reducing the number of false negatives and future infections. Crucially, the method can also be easily adapted to the evaluation of other digital readers for lateral flow type devices,” added Professor Camila Caiado, Professor of Statistics at Durham University and chief statistician on the project.

Related Links:
University of Birmingham
Durham University
Oxford University


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researcher Joris Deelen (Photo courtesy of Elton Alisson/Agência FAPESP)

Blood-Based Score May Support Targeted Interventions for Healthier Aging

Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test Identifies Early Breast and Prostate Cancer Signals Years Before Diagnosis

Breast and prostate cancers are among the most common cancers, yet many are detected only after tumors have become established. Identifying disease earlier could support closer monitoring and help distinguish... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.